61
Participants
Start Date
March 3, 2022
Primary Completion Date
February 6, 2025
Study Completion Date
April 28, 2025
Basimglurant with crossover to Placebo
Basimglurant with crossover to Placebo
Placebo with crossover to Basimglurant
Placebo with crossover to Basimglurant
Boston Children's Health Physicians (BCHP) (Site #: 111), Hawthorne
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda (Site # 183), Milan
Kennedy Krieger Institute (Site #: 110), Baltimore
Hospital Regional Universitario de Malaga - Hospital General (Site # 193), Málaga
Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi (Site #: 905), Fatih
Istanbul Egitim ve Arastirma Hastanesi (Site #: 901), Sultangazi
Yeditepe University Kosuyolu Hospital (Site #: 904), Kadıköy
Centro de Neurología Avanzada (Site # 191), Seville
David Geffen School of Medicine at UCLA (Site #: 101), Los Angeles
Hadassah Medical Center - PPDS (Site #: 503), Jerusalem
All India Institute of Medical Sciences (Site # 804), New Delhi
Jaslok Hospital and Research Centre (Site # 801), Mumbai
Deenanath Mangeshkar Hospital and Research Centre (Site # 805), Pune
Citi Neuro Centre (Site # 806), Hyderabad
Rainbow Childrens Hospital (Site # 803), Hyderabad
Christian Medical College (Site # 807), Vellore
Boston Children's Hospital (Site #: 102), Boston
William Beaumont Hospital - Royal Oak (Site #: 104), Royal Oak
Minnesota Epilepsy Group PA (Site #: 105), Roseville
Duke Children's Hospital and Health Center (Site #: 106), Durham
University Hospitals Cleveland Medical Center, Rainbow Babies and Childrens Hospital (Site #: 107), Cleveland
The University of Texas Medical School at Houston (Site #: 103), Houston
Instytut Pomnik Centrum Zdrowia Dziecka (Site # 262), Warsaw
Hospital Universitario Germans Trias i Pujol (Site # 194), Badalona
Hospital Sant Joan de Deu - PIN (Site # 192), Esplugues de Llobregat
Salford Royal Hospital - PPDS (Site # 304), Salford
Noahs Ark Children's Hospital (Site # 306), Cardiff
Lead Sponsor
Noema Pharma AG
INDUSTRY